Export financials
Integer Holdings Corporation (ITGR)
The export includes the complete available history of financial statements and ratios. Numbers are provided in full, without million or billion abbreviations, in their original reporting units.
CSV downloads as a ZIP archive with one file for each report and frequency.

Integer Holdings Corporation Balance Sheet 2025-2009 | ITGR
Brief overview of Integer Holdings Corporation's balance sheet structure
The balance sheet is assessed across five available annual reports spanning 2021 to 2025.
Over the period, assets gained +32.1%, moving from $2.6 billion to $3.4 billion. CAGR near 7.2% shows consistent growth.
Liabilities followed the scale of the balance sheet: +35.6% versus +32.1% for assets. Leverage did not change materially.
The equity ratio reached 51.2% from 52.5%. A high capital share reduces dependence on liabilities.
Net debt equals about 0.67x of equity. The burden is manageable, but further growth would warrant attention.
Cash represents 0.5% of assets versus 0.7% initially, showing how the immediate liquidity reserve changed.
By the end of the period, accumulated earnings were $994.1 million; the change from the start was +61.8%.
Conclusion
Integer Holdings Corporation's balance sheet is broadly resilient, though selected areas require monitoring. The balance between assets, equity and liabilities remains the key issue.
Annual Balance Sheet Integer Holdings Corporation
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Debt |
1.18 B | 941 M | 945 M | 893 M | 805 M | 653 M | 801 M | 900 M | 1.57 B | 1.63 B | 110 M | 162 M | - | 205 M | 200 M | 198 M | - |
Long Term Debt |
1.19 B | 980 M | 960 M | 907 M | 813 M | 694 M | 777 M | 888 M | 1.58 B | 1.69 B | 175 M | 198 M | - | 225 M | 236 M | 221 M | - |
Long Term Debt Current |
9.1 M | 7.35 M | 8.56 M | 10.4 M | 9.86 M | 8.43 M | 7.51 M | 37.5 M | 30.5 M | 31.3 M | 11.2 M | - | - | - | - | - | - |
Total Non Current Liabilities |
1.43 B | 1.23 B | 1.2 B | 1.15 B | 1.07 B | 945 M | 1.02 B | 1.1 B | 1.75 B | 1.92 B | 233 M | 257 M | - | 317 M | 320 M | 290 M | - |
Total Current Liabilities |
232 M | 227 M | 221 M | 224 M | 160 M | 156 M | 179 M | 165 M | 209 M | 185 M | 109 M | 91.8 M | - | 91.8 M | 94 M | 60.6 M | - |
Total Liabilities |
1.66 B | 1.46 B | 1.42 B | 1.38 B | 1.23 B | 1.1 B | 1.2 B | 1.27 B | 1.95 B | 2.13 B | 342 M | 349 M | - | 409 M | 414 M | 350 M | - |
Deferred Revenue |
5.21 M | 4.44 M | 6.14 M | 5.62 M | 3.78 M | 2.5 M | 1.98 M | 2.48 M | 4.15 M | 3.59 M | 6.17 M | 6.01 M | - | 7.68 M | 7.83 M | - | - |
Retained Earnings |
994 M | 891 M | 771 M | 681 M | 614 M | 518 M | 440 M | 344 M | 176 M | 232 M | 239 M | 184 M | - | 148 M | 152 M | 119 M | - |
Total Assets |
3.41 B | 3.08 B | 2.94 B | 2.79 B | 2.58 B | 2.37 B | 2.35 B | 2.33 B | 2.85 B | 2.98 B | 955 M | 891 M | - | 890 M | 881 M | 777 M | - |
Cash and Cash Equivalents |
17.2 M | 46.5 M | 23.7 M | 24.3 M | 17.9 M | 49.2 M | 13.5 M | 25.6 M | 44.1 M | 52.1 M | 76.8 M | 35.5 M | - | 20.3 M | 36.5 M | 22.9 M | 22.1 M |
Book Value |
1.75 B | 1.62 B | 1.52 B | 1.42 B | 1.35 B | 1.27 B | 1.15 B | 1.06 B | 893 M | 851 M | 613 M | 542 M | - | 481 M | 467 M | 427 M | - |
Total Shareholders Equity |
1.75 B | 1.62 B | 1.52 B | 1.42 B | 1.35 B | 1.27 B | 1.15 B | 1.06 B | 893 M | 725 M | 613 M | 542 M | - | 481 M | 467 M | 427 M | 375 M |
Annual performance
Select metrics to display
All numbers in USD currency
Quarterly Balance Sheet Integer Holdings Corporation
| 2026-Q3 | 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Long Term Debt |
67.4 M | 67.1 M | 69.3 M | 81.9 M | 82.7 M | 83.9 M | 85.7 M | 77.7 M | 69.1 M | 71.9 M | 74.3 M | 72.1 M | 57.3 M | 60 M | 62 M | 64 M | 62 M | 64.4 M | 64.3 M | 59.8 M | 41.4 M | 43.1 M | 45.2 M | 37.9 M | 39 M | 40.6 M | 42.5 M | 37.1 M | 38.7 M | 39.8 M | 33.8 M | 888 M | 954 M | 1.54 B | 1.56 B | 1.61 B | 1.63 B | 1.67 B | 1.7 B | 1.73 B | 1.75 B | 1.76 B | 1.76 B | 1.71 B | 180 M | 182 M | 185 M | 187 M | 190 M | 192 M | 195 M | 198 M | 210 M | 237 M | 233 M | 225 M | 230 M | 233 M | 239 M | 236 M | 198 M | 206 M | 236 M |
Total Non Current Liabilities |
1.47 B | 1.49 B | 1.51 B | 1.43 B | 1.44 B | 1.45 B | 1.48 B | 1.23 B | 1.32 B | 1.37 B | 1.39 B | 1.2 B | 1.17 B | 1.22 B | 1.23 B | 1.15 B | 1.18 B | 1.2 B | 1.07 B | 1.07 B | 859 M | 880 M | 904 M | 945 M | 1.06 B | 1.19 B | 1.05 B | 1.02 B | 1.04 B | 1.08 B | 1.12 B | 1.1 B | 1.14 B | 1.66 B | 1.7 B | 1.75 B | 1.82 B | 1.87 B | 1.89 B | 1.92 B | 1.94 B | 1.96 B | 1.96 B | 1.92 B | 220 M | 226 M | 231 M | 233 M | 244 M | 250 M | 254 M | 257 M | 269 M | 295 M | 293 M | 317 M | 319 M | 320 M | 325 M | 320 M | 274 M | 281 M | - |
Total Liabilities |
1.67 B | 1.7 B | 1.71 B | 1.66 B | 1.65 B | 1.67 B | 1.69 B | 1.46 B | 1.55 B | 1.57 B | 1.59 B | 1.42 B | 1.38 B | 1.42 B | 1.46 B | 1.38 B | 1.38 B | 1.39 B | 1.24 B | 1.23 B | 1.02 B | 1.04 B | 1.07 B | 1.1 B | 1.22 B | 1.34 B | 1.23 B | 1.2 B | 1.23 B | 1.26 B | 1.29 B | 1.27 B | 1.32 B | 1.89 B | 1.93 B | 1.95 B | 2.03 B | 2.06 B | 2.1 B | 2.11 B | 2.14 B | 2.18 B | 2.18 B | 2.13 B | 338 M | 325 M | 318 M | 342 M | 334 M | 328 M | 324 M | 349 M | 360 M | 394 M | 396 M | 409 M | 411 M | 402 M | 404 M | 414 M | 348 M | 356 M | 414 M |
Deferred Revenue |
5.68 M | 4.47 M | 5.38 M | 5.21 M | 3.71 M | 4.23 M | 4.06 M | 4.44 M | 4.99 M | 5.07 M | 5.93 M | 6.14 M | 5.82 M | 8.78 M | 6.37 M | 5.62 M | 6.16 M | 8.72 M | 7.02 M | 3.78 M | 2.86 M | 2.52 M | 2.38 M | 2.5 M | 1.93 M | 2.42 M | 3.16 M | 1.98 M | 2.08 M | 2.36 M | 1.99 M | 2.48 M | 4.1 M | 3.2 M | 4.4 M | 2.2 M | - | 2.2 M | 3.6 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Retained Earnings |
1.05 B | 1.03 B | 1.01 B | 994 M | 945 M | 906 M | 869 M | 891 M | 859 M | 823 M | 792 M | 771 M | 745 M | 718 M | 694 M | 681 M | 663 M | 647 M | 626 M | 614 M | 591 M | 568 M | 539 M | 518 M | 502 M | 472 M | 471 M | 440 M | 429 M | 399 M | 366 M | 344 M | 318 M | 204 M | 184 M | 176 M | 122 M | 108 M | 105 M | 109 M | 101 M | 89.7 M | 90.5 M | 232 M | 257 M | 257 M | 247 M | 239 M | 225 M | 211 M | 199 M | 184 M | 174 M | 163 M | 153 M | 148 M | 153 M | 161 M | 157 M | 153 M | 147 M | 140 M | 153 M |
Total Assets |
3.39 B | 3.42 B | 3.41 B | 3.41 B | 3.4 B | 3.37 B | 3.3 B | 3.08 B | 3.17 B | 3.13 B | 3.12 B | 2.94 B | 2.84 B | 2.86 B | 2.87 B | 2.79 B | 2.74 B | 2.76 B | 2.61 B | 2.58 B | 2.35 B | 2.36 B | 2.34 B | 2.37 B | 2.45 B | 2.52 B | 2.4 B | 2.35 B | 2.36 B | 2.37 B | 2.37 B | 2.33 B | 2.36 B | 2.81 B | 2.85 B | 2.85 B | 2.85 B | 2.84 B | 2.84 B | 2.83 B | 2.88 B | 2.9 B | 2.91 B | 2.98 B | 984 M | 966 M | 947 M | 955 M | 931 M | 912 M | 890 M | 890 M | 885 M | 897 M | 885 M | 890 M | 892 M | 886 M | 887 M | 881 M | 812 M | 820 M | 881 M |
Cash and Cash Equivalents |
14.1 M | 21.4 M | 8.12 M | 17.2 M | 58.9 M | 23.1 M | 31.7 M | 46.5 M | 35.6 M | 34.1 M | 42.2 M | 23.7 M | 32.1 M | 38.6 M | 40.6 M | 24.3 M | 20.2 M | 15.6 M | 25.7 M | 17.9 M | 25.5 M | 30.6 M | 28.4 M | 49.2 M | 99.9 M | 206 M | 37.3 M | 13.5 M | 14.7 M | 15.9 M | 13.5 M | 25.6 M | 22.9 M | 18.9 M | 29.5 M | 44.1 M | 43.6 M | 41 M | 54.9 M | 52.1 M | 45 M | 36.6 M | 54.1 M | 82.5 M | 68.6 M | 72.3 M | 67 M | 76.8 M | 61.6 M | 51.2 M | 38.3 M | 35.5 M | 4.97 M | 10.2 M | 10.1 M | 20.3 M | 10.8 M | 11.1 M | 9.53 M | 36.5 M | 41.6 M | 36.9 M | 36.5 M |
Book Value |
1.73 B | 1.72 B | 1.7 B | 1.75 B | 1.75 B | 1.7 B | 1.61 B | 1.62 B | 1.62 B | 1.55 B | 1.53 B | 1.52 B | 1.46 B | 1.45 B | 1.42 B | 1.42 B | 1.36 B | 1.36 B | 1.36 B | 1.35 B | 1.33 B | 1.31 B | 1.28 B | 1.27 B | 1.23 B | 1.18 B | 1.16 B | 1.15 B | 1.13 B | 1.11 B | 1.08 B | 1.06 B | 1.04 B | 918 M | 920 M | 893 M | 823 M | 783 M | 741 M | 725 M | 741 M | 723 M | 732 M | 851 M | 646 M | 642 M | 628 M | 613 M | 597 M | 583 M | 567 M | 541 M | 524 M | 503 M | 489 M | 481 M | 481 M | 484 M | 483 M | 467 M | 464 M | 464 M | 467 M |
Total Shareholders Equity |
1.73 B | 1.72 B | 1.7 B | 1.75 B | 1.75 B | 1.7 B | 1.61 B | 1.62 B | 1.62 B | 1.55 B | 1.53 B | 1.52 B | 1.46 B | 1.45 B | 1.42 B | 1.42 B | 1.36 B | 1.36 B | 1.36 B | 1.35 B | 1.33 B | 1.31 B | 1.28 B | 1.27 B | 1.23 B | 1.18 B | 1.16 B | 1.15 B | 1.13 B | 1.11 B | 1.08 B | 1.06 B | 1.04 B | 918 M | 920 M | 893 M | 823 M | 783 M | 741 M | 725 M | 741 M | 723 M | 732 M | 851 M | 646 M | 642 M | 628 M | 613 M | 597 M | 583 M | 567 M | 542 M | 524 M | 503 M | 489 M | 481 M | 481 M | 484 M | 483 M | 467 M | 464 M | 464 M | 467 M |
Quarterly performance
Select metrics to display
All numbers in USD currency
Balance Sheet is a fundamental financial report of Integer Holdings Corporation, providing a complete picture of the company’s financial position at a specific point in time. Unlike the income statement, which records the results of operations over a certain period, the balance sheet shows what assets the company owns, what liabilities it has to creditors, and what equity is available to the owners.
For an investor, the balance sheet is important because it allows assessing the company’s financial stability, understanding how much debt it carries, and how dependent it is on borrowed financing. It helps calculate key liquidity and leverage ratios. When analyzing, attention should be paid to the debt-to-equity ratio (Debt/Equity), the amount of cash on the balance sheet, and the ratio of current liabilities to liquid assets.
Features of balance sheet analysis- Vertical and horizontal analysis
Vertical analysis shows the structure of the balance sheet as a percentage of total assets or liabilities, while horizontal analysis shows the dynamics of changes over multiple periods. - Asset quality
It is important to evaluate not only the amount of assets but also their liquidity and realizability. - Accounting for off-balance sheet liabilities
Some liabilities may not be directly reflected in the balance sheet, which requires additional attention.
Balance sheet of other industry stocks – Medical devices
| Issuer | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|
|
Apollo Endosurgery
APEN
|
- | - | $ 475 M | ||
|
NuVasive
NUVA
|
- | - | $ 2.07 B | ||
|
Conformis
CFMS
|
- | - | $ 16.4 M | ||
|
ViewRay
VRAY
|
- | 1.54 % | $ 468 M | ||
|
Medigus Ltd.
MDGS
|
- | 10.28 % | $ 55.5 M | ||
|
Abbott Laboratories
ABT
|
$ 103.08 | -0.98 % | $ 179 B | ||
|
Align Technology
ALGN
|
$ 154.77 | -3.07 % | $ 11.2 B | ||
|
Vapotherm
VAPO
|
- | 6.72 % | $ 34 M | ||
|
Silk Road Medical, Inc
SILK
|
- | - | $ 1.07 B | ||
|
Alphatec Holdings
ATEC
|
$ 6.66 | -3.48 % | $ 999 M | ||
|
Boston Scientific Corporation
BSX
|
$ 41.95 | -2.43 % | $ 62.1 B | ||
|
Natus Medical Incorporated
NTUS
|
- | 1.94 % | $ 1.05 B | ||
|
Nemaura Medical
NMRD
|
- | -17.8 % | $ 2.74 M | ||
|
Butterfly Network
BFLY
|
$ 5.39 | -8.28 % | $ 1.33 B | ||
|
Bio-Rad Laboratories
BIO
|
$ 358.56 | -2.43 % | $ 9.78 B | ||
|
Edwards Lifesciences Corporation
EW
|
$ 101.86 | -1.94 % | $ 59.6 B | ||
|
Aethlon Medical
AEMD
|
$ 5.49 | 13.33 % | $ 3.7 M | ||
|
Apyx Medical Corporation
APYX
|
$ 2.39 | 2.06 % | $ 98.2 M | ||
|
GenMark Diagnostics, Inc.
GNMK
|
- | - | $ 1.77 B | ||
|
Cognyte Software Ltd.
CGNT
|
$ 7.27 | -6.56 % | $ 530 M | ||
|
Lianluo Smart Limited
LLIT
|
- | 24.59 % | $ 44.8 M | ||
|
Obalon Therapeutics, Inc.
OBLN
|
- | -5.86 % | $ 30.6 M | ||
|
Medtronic PLC
MDT
|
$ 99.64 | -1.0 % | $ 128 B | ||
|
Myomo
MYO
|
$ 0.81 | -3.74 % | $ 33.9 M | ||
|
Establishment Labs Holdings
ESTA
|
$ 69.2 | -0.59 % | $ 2.05 B | ||
|
Insulet Corporation
PODD
|
$ 133.09 | -3.02 % | $ 9.36 B | ||
|
Profound Medical Corp.
PROF
|
$ 6.39 | -3.03 % | $ 193 M | ||
|
Delcath Systems
DCTH
|
$ 18.77 | -2.44 % | $ 672 M | ||
|
Electromed
ELMD
|
$ 23.03 | -1.46 % | $ 190 M | ||
|
Inogen
INGN
|
$ 5.3 | -2.31 % | $ 141 M | ||
|
Globus Medical
GMED
|
$ 66.85 | -2.55 % | $ 9.04 B | ||
|
Sintx Technologies
SINT
|
$ 1.13 | -4.24 % | $ 3.13 M | ||
|
IRadimed Corporation
IRMD
|
$ 81.04 | -0.25 % | $ 1.03 B | ||
|
Penumbra
PEN
|
$ 319.13 | -0.27 % | $ 12.4 B | ||
|
Smith & Nephew plc
SNN
|
$ 29.85 | 0.05 % | $ 25.9 B | ||
|
ClearPoint Neuro
CLPT
|
$ 6.91 | -5.47 % | $ 196 M | ||
|
Sensus Healthcare
SRTS
|
$ 2.28 | -3.39 % | $ 37.2 M | ||
|
Accuray Incorporated
ARAY
|
$ 2.1 | -1.18 % | $ 258 M | ||
|
Stryker Corporation
SYK
|
$ 309.41 | -1.24 % | $ 118 B | ||
|
Hancock Jaffe Laboratories, Inc.
HJLI
|
- | -1.98 % | $ 98.3 M | ||
|
AxoGen
AXGN
|
$ 55.74 | -1.08 % | $ 2.57 B | ||
|
Tactile Systems Technology
TCMD
|
$ 25.62 | -1.42 % | $ 586 M | ||
|
Quanterix Corporation
QTRX
|
$ 1.95 | -3.94 % | $ 83.1 M | ||
|
TELA Bio
TELA
|
$ 0.69 | -4.9 % | $ 32.4 M | ||
|
IRIDEX Corporation
IRIX
|
$ 0.45 | -4.57 % | $ 7.62 M | ||
|
Cytosorbents Corporation
CTSO
|
$ 4.37 | -14.76 % | $ 272 M | ||
|
TransMedics Group
TMDX
|
$ 85.17 | -9.42 % | $ 2.9 B | ||
|
Integra LifeSciences Holdings Corporation
IART
|
$ 13.25 | -2.21 % | $ 1.02 B | ||
|
Nano-X Imaging Ltd.
NNOX
|
$ 0.23 | -2.13 % | $ 14.9 M |